Frontlight ResearchEarly access
Taking people in United StatesNo phase
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Key facts
- Who runs it
- PSC Partners Seeking a Cure
- Where
- Boston, Dallas, Indianapolis, Miami, New Haven, Richmond, Rochester, Sacramento, and San Francisco, United StatesSee the 11 sitesAlso in 5 other countries, 7 sites
- Trial code
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 6 May 2024
- Expected to end
- Jan 2031
- Type of study
- Observational
- Record updated
- 13 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF)
- Confirmed clinical diagnosis of large duct PSC
Who cannot take part
- Clinically diagnosed infections (including acute cholangitis) and receiving treatment within the past 7 days; patients on chronic suppressive antibiotics for acute cholangitis will be allowed to enroll
- Prior liver transplantation
- Participants who are currently participating in an investigational PSC therapy clinical study or who have participated in such a study within the past 12 weeks
- Clinically significant acute or chronic liver disease of an etiology other than PSC (including but not limited to metabolic-dysfunction associated steatohepatitis (MASH), PBC, HCV, HBV, or alcoholic hepatitis, Wilson's disease, alpha-1 antitryp-sin deficiency, acute or chronic drug-induced liver injury); Patients with PSC and elements of AIH overlap are allowed to enroll; Patients with metabolic dysfunction associated steatotic liver disease (MASLD) or benign steatosis are allowed to enroll
- Evidence of current or historical decompensated cirrhosis based on the following clinical events:; Ascites > Grade 2 and requiring treatment; Esophageal or gastric variceal bleeding requiring hospitalization; Hepatic encephalopathy (as defined by a West Haven score ≥ 2); Spontaneous bacterial peritonitis defined as ascites absolute neutrophil count >250/mm3 in the absence of an intra-abdominal source of infection; AKI-HRS according to AASLD Guidelines (Flamm 2021); Portal hypertension based on a platelet count < 150 × 109/L and LSM > 15 kPa with clinical, laboratory, imaging and/or other relevant parameters
- MELD 3.0 Score >15. For subjects on anticoagulation medication, baseline INR determination for MELD score calculation should take this use into account
- History, evidence, or high suspicion of hepatobiliary malignancies or active colon cancer based on imaging, screening laboratory values, and/or clinical symptoms. Patients with a history of colon cancer who have undergone a colectomy and have no current evidence of colon cancer will be allowed to enroll in the study
- Participants with current clinical or laboratory evidence of any severe, progressive, or uncontrolled disease, related or unrelated to PSC and which, in the opinion of the investigator, has an expected survival of less than 52 weeks
- Small-Duct PSC
- Clinically diagnosed secondary or IgG4-related sclerosing cholangitis
- Hospitalization in the past 7 days
- UDCA dose >28 mg/kg
- Participants who are impaired, incapacitated, or incapable of completing study-related assessments or giving informed consent
- Prisoners or participants who are involuntarily incarcerated
- Absence of data in medical records to assess inclusion and exclusion criteria
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 5 other countries, 7 sites
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Julie SheaTaking people
- Massachusetts General HospitalBoston, United StatesContact: Gary ZhangTaking people
- UT Southwestern Medical CenterDallas, United StatesContact: Stephen Rossi, PharmDNo longer taking part
- Indiana UniversityIndianapolis, United StatesContact: Rebecca GerstorffTaking people
- Schiff Center for Liver Diseases/University of MiamiMiami, United StatesContact: Cynthia Levy, MDTaking people
- Yale UniversityNew Haven, United StatesContact: Marina SilveiraTaking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Caitlin Hurst, BSTaking people
- Mayo ClinicRochester, United StatesContact: Paige PowrieTaking people
- UC DavisSacramento, United StatesContact: Samrrah RaoufTaking people
- California Pacific Medical CenterSan Francisco, United StatesContact: Stefanie Roberts, BSTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Fawzy BarryTaking people
About the trial
What the trial wants to find out
Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.
The group in the trial
- Adult patients with a confirmed diagnosis of large duct PSC.
1. Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF). 2. Confirmed clinical diagnosis of large duct PSC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Global Multi-Center Prospective Observational Cohort to Support Drug Development in Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC)
- Fit questions
- Built from NCT06297993, who can take part
- Record updated
- 13 October 2026